The aim of this study is to describe the use of Instanyl® (Intranasal fentanyl spray) in the treatment of breakthrough pain (BTP) in cancer patients by success of dose titration and distribution of dose strength. Data will be collected at three different time points over a 3 month period.
Study Type
OBSERVATIONAL
Enrollment
309
Success of titration (Y/N), defined as reaching a maintenance dose
Time frame: At week 4 and month 3 after baseline
Dose level of Instanyl® after titration, defined as the maintenance dose
Time frame: At week 4 and month 3 after baseline
Adverse Drug Reactions (ADR)
Time frame: At week 4 and month 3 after baseline
Reason and time for Instanyl® termination
Time frame: At week 4 and month 3 after baseline
Change in Instanyl® maintenance dose
Time frame: At week 4 and month 3 after baseline
Change in level of background medication (standardised daily dose)
Time frame: At week 4 and month 3 after baseline
Pain, pain relief and impact of pain of daily life
Time frame: At baseline and week 4
Treatment satisfaction
Time frame: At baseline and week 4
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Investigational site
Copenhagen, Denmark
Investigational site
Herning, Denmark
Investigational site
Hillerød, Denmark
Investigational site
Randers, Denmark
Investigational site
Aix-en-Provence, France
Investigational site
Amiens, France
Investigational site
Argenteuil, France
Investigational site
Auxerre, France
Investigational site
Besançon, France
Investigational site
Blois, France
...and 55 more locations